
簡(jiǎn)要描述:Loxoprofen 68767-14-6描述Loxoprofen is a non-steroidal anti-inflammatory drug.
產(chǎn)品分類(lèi)
Product Category詳細(xì)介紹
| 品牌 | absin | CAS | 68767-14-6 |
|---|---|---|---|
| 分子式 | 68767-14-6 | 純度 | 98% |
| 分子量 | 246.3 | 貨號(hào) | abs47027081 |
| 規(guī)格 | 10mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | is a non-steroidal anti-inflammatory dr | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
Loxoprofen 68767-14-6
| 產(chǎn)品描述 | |
| 描述 | Loxoprofen is a non-steroidal anti-inflammatory drug. |
| 純度 | 98% |
| 儲(chǔ)存/保存方法 | Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 洛索洛芬 |
| 外觀 | 白色至淡黃色結(jié)晶粉末 |
| 可溶性/溶解性 | DMSO : 46 mg/mL (186.8 mM) Ethanol : 46 mg/mL (186.8 mM) |
| 生物活性 | |
| In vitro(體外研究) | Loxoprofen sodium(LOX) does not affect the proliferation and viability of LLC cells in vitro. HUVECs treated with LOX results in the inhibition of the tubular formation. Treatment with 50 mg/ml LOX reveals a 33% decline in in vitro angiogenesis, compared with vehicle-treated HUVECs. This inhibition is presumably due to inhibition of VEGF activity. |
| In vivo(體內(nèi)研究) | Loxoprofen sodium (LOX), inhibits in vivo growth of implanted Lewis lung carcinoma (LLC). Intratumoral vessel density in LOX-treated mice is significantly lower than that of mice without treatment. Intratumoral expressions of vascular endothelial growth factor (VEGF) mRNA are attenuated by the LOX treatment. LOX suppresses both intratumoral and systemic VEGF protein in LLC-implanted mice. LOX alsoinhibits tubular formation of primary cultured human umbilical vein endothelial cells, presumably due to the inhibition of VEGF. In patients with advanced non-small cell lung cancer, LOX medication (120 mg/day) for a week significantly decreases the plasma VEGF level. |
| 參考文獻(xiàn) | |
| 參考文獻(xiàn) |
|
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | Immunology Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
